Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Javed Butler(Saint Luke's Health System), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Cordula Zeller(Inserm), Janet Schnee(Boehringer Ingelheim (United States)), João Pedro Ferreira(Inserm), Milton Packer(Baylor University Medical Center), Martina Brueckmann
Cited by 253
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k